Soliris a 'Game Changer' for Genetic Disorder (CME/CE)
(MedPage Today) -- Long-term treatment with the humanized monoclonal antibody eculizumab (Soliris) was highly effective in thwarting thrombotic microangiopathy and improving kidney function in atypical hemolytic-uremic syndrome, researchers found.
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news
More News: Cancer & Oncology | Genetics | Hematology | Hemolytic Uremic Syndrome (HUS) | Urology & Nephrology